Magna Pharmacia at the EAN Congress – Latest Achievements in the Use of Intravenous Immunoglobulins in Neurology

Magna Pharmacia participated in the EAN Congress (European Academy of Neurology Congress), one of the most significant international professional events in the field of neurology, bringing together leading experts and researchers from around the world.

During the congress, the latest scientific and clinical data in the field of diagnostics and treatment of neurological diseases were presented, with a special focus on the use of intravenous immunoglobulins (IVIG) in the therapy of immunologically mediated diseases. Professional sessions covered current recommendations and clinical experiences in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), and autoimmune encephalitis, where IVIG represents an important therapeutic option in accordance with current international guidelines and individual patient assessment.

The EAN Congress provided an opportunity for knowledge exchange, familiarization with the latest results of clinical research, and discussion of modern therapeutic approaches that contribute to improving the quality of treatment and outcomes in patients with neurological diseases.

By participating in this congress, Magna Pharmacia confirms its commitment to continuing medical education, monitoring of modern scientific achievements, and providing support to healthcare professionals in the application of innovative therapeutic solutions.